Dashboard
1
The company has declared positive results for the last 3 consecutive quarters
- NET SALES(HY) At CNY 156.3 MM has Grown at 92.49%
- OPERATING CASH FLOW(Y) Highest at CNY 86.49 MM
- NET PROFIT(HY) Higher at CNY 25.32 MM
2
With ROE of 5.26%, it has a fair valuation with a 8.60 Price to Book Value
3
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,937 Million (Small Cap)
157.00
NA
0.00%
0.35
5.26%
9.47
Revenue and Profits:
Net Sales:
48 Million
(Quarterly Results - Mar 2026)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.58%
0%
6.58%
6 Months
22.57%
0%
22.57%
1 Year
15.85%
0%
15.85%
2 Years
102.92%
0%
102.92%
3 Years
47.95%
0%
47.95%
4 Years
101.66%
0%
101.66%
5 Years
137.65%
0%
137.65%
Hainan Shuangcheng Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.72%
EBIT Growth (5y)
19.07%
EBIT to Interest (avg)
-4.12
Debt to EBITDA (avg)
15.09
Net Debt to Equity (avg)
0.46
Sales to Capital Employed (avg)
0.33
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.03%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
157
Industry P/E
Price to Book Value
8.26
EV to EBIT
123.15
EV to EBITDA
50.51
EV to Capital Employed
6.36
EV to Sales
12.47
PEG Ratio
1.28
Dividend Yield
NA
ROCE (Latest)
5.16%
ROE (Latest)
5.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
48.40
107.90
-55.14%
Operating Profit (PBDIT) excl Other Income
2.50
32.90
-92.40%
Interest
2.30
2.40
-4.17%
Exceptional Items
0.10
-0.40
125.00%
Consolidate Net Profit
-0.60
16.20
-103.70%
Operating Profit Margin (Excl OI)
52.40%
173.00%
-12.06%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -55.14% vs 27.24% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -103.70% vs 2.53% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
275.70
168.40
63.72%
Operating Profit (PBDIT) excl Other Income
72.50
-16.30
544.79%
Interest
9.70
9.30
4.30%
Exceptional Items
-2.70
-29.00
90.69%
Consolidate Net Profit
8.90
-106.30
108.37%
Operating Profit Margin (Excl OI)
62.90%
-426.10%
48.90%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 63.72% vs -28.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 108.37% vs -47.64% in Dec 2024
About Hainan Shuangcheng Pharmaceuticals Co., Ltd. 
Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






